[{"data":1,"prerenderedAt":246},["ShallowReactive",2],{"drug-darbepoetin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":53,"contraindications":125,"warnings":135,"renal":145,"monitoring":146,"interactions":147,"review":148,"examples":151,"atc":174,"iran":176,"usApproval":188,"links":194,"populations":212},"darbepoetin",1,{"fa":7,"en":8},"داربپوئتین آلفا","Darbepoetin alfa","blood",{"fa":11,"en":12},"محرک خون‌سازی (ESA) طولانی‌اثر","Long-acting erythropoiesis-stimulating agent",[14],{"name":15,"market":16},"Aranesp","US",[18,19,20],"aranesp","آرانسپ","داربپوئتین",[22,36,45],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"syr-40","injection","sc","40 mcg\u002F0.4 mL prefilled syringe",{"amount":28,"unit":29,"perVolumeMl":30},40,"mcg",0.4,[16],[33],{"source":34,"section":35},"fda-aranesp","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":42,"refs":43},"syr-100","100 mcg\u002F0.5 mL prefilled syringe",{"amount":40,"unit":29,"perVolumeMl":41},100,0.5,[16],[44],{"source":34,"section":35},{"id":46,"form":24,"route":25,"label":47,"concentration":48,"markets":50,"refs":51},"syr-500","500 mcg\u002F1 mL prefilled syringe",{"amount":49,"unit":29,"perVolumeMl":5},500,[16],[52],{"source":34,"section":35},[54,81,92,104],{"id":55,"disease":56,"label":57,"population":60,"type":64,"unit":29,"dose":65,"refs":68,"durationDays":71,"notes":72},"dial","anemia-ckd",{"fa":58,"en":59},"کم‌خونی CKD روی دیالیز — شروع ۰٫۴۵ mcg\u002Fkg هفتگی (یا ۰٫۷۵ هر ۲ هفته)، وریدی ترجیحاً","CKD anaemia on dialysis — start 0.45 mcg\u002Fkg weekly (or 0.75 every 2 weeks), IV preferred",{"minAge":61},{"value":62,"unit":63},18,"year","weightBased",{"perKgPerDose":66,"intervalHours":67},0.45,24,[69],{"source":34,"section":70},"2.2",{"min":5,"max":5},[73],{"text":74,"refs":77},{"fa":75,"en":76},"هموگلوبین را بالای ۱۱ g\u002FdL هدف نگیرید؛ کمترین دوز برای کاهش تزریق خون. پیش از شروع آهن (فریتین \u003C۱۰۰ یا اشباع \u003C۲۰٪ مکمل).","Do not target haemoglobin >11 g\u002FdL; lowest dose to reduce transfusions. Check iron first (supplement if ferritin \u003C100 or saturation \u003C20%).",[78,79],{"source":34,"section":70},{"source":34,"section":80},"2.1",{"id":82,"disease":56,"label":83,"population":86,"type":64,"unit":29,"dose":88,"refs":89,"durationDays":91},"nondial",{"fa":84,"en":85},"کم‌خونی CKD بدون دیالیز — شروع ۰٫۴۵ mcg\u002Fkg هر ۴ هفته","CKD anaemia not on dialysis — start 0.45 mcg\u002Fkg every 4 weeks",{"minAge":87},{"value":62,"unit":63},{"perKgPerDose":66,"intervalHours":67},[90],{"source":34,"section":70},{"min":5,"max":5},{"id":93,"disease":56,"label":94,"population":97,"type":64,"unit":29,"dose":99,"refs":100,"durationDays":103},"child",{"fa":95,"en":96},"کودک با CKD — شروع ۰٫۴۵ mcg\u002Fkg هفتگی (بدون دیالیز: یا ۰٫۷۵ هر ۲ هفته)","Children with CKD — start 0.45 mcg\u002Fkg weekly (not on dialysis: or 0.75 every 2 weeks)",{"maxAge":98},{"value":62,"unit":63},{"perKgPerDose":66,"intervalHours":67},[101],{"source":34,"section":102},"2",{"min":5,"max":5},{"id":105,"disease":106,"label":107,"population":110,"type":64,"unit":29,"dose":112,"refs":114,"durationDays":117,"notes":118},"chemo","chemotherapy-induced-anemia",{"fa":108,"en":109},"کم‌خونی ناشی از شیمی‌درمانی (Hb \u003C۱۰) — ۲٫۲۵ mcg\u002Fkg زیرجلدی هفتگی","Chemotherapy-induced anaemia (Hb \u003C10) — 2.25 mcg\u002Fkg SC weekly",{"minAge":111},{"value":62,"unit":63},{"perKgPerDose":113,"intervalHours":67},2.25,[115],{"source":34,"section":116},"2.3",{"min":5,"max":5},[119],{"text":120,"refs":123},{"fa":121,"en":122},"یا ۵۰۰ mcg هر ۳ هفته. فقط اگر دست‌کم ۲ ماه شیمی‌درمانی باقی است؛ تا پایان دوره.","Or 500 mcg every 3 weeks. Only with ≥2 more months of planned chemotherapy; until the course ends.",[124],{"source":34,"section":116},[126],{"id":127,"severity":128,"text":129,"refs":132},"ci","block",{"fa":130,"en":131},"فشار خون کنترل‌نشده؛ آپلازی خالص گلبول قرمز پس از ESA؛ واکنش آلرژیک جدی.","Uncontrolled hypertension; pure red cell aplasia after ESA therapy; serious allergic reactions.",[133],{"source":34,"section":134},"4",[136],{"text":137,"refs":140},{"fa":138,"en":139},"هشدار جعبه‌ای: افزایش مرگ، MI، سکته، ترومبوز و رشد تومور؛ در سرطان فقط کم‌خونی ناشی از شیمی‌درمانی میلوساپرسیو، نه درمان علاج‌بخش. فشار خون؛ تشنج.","Boxed warning: increased death, MI, stroke, thrombosis and tumour progression; in cancer only for myelosuppressive-chemotherapy anaemia, not curative intent. Hypertension; seizures.",[141,143],{"source":34,"section":142},"Boxed Warning",{"source":34,"section":144},"5",[],[],[],{"status":149,"reviewer":150,"date":150},"unverified",null,[152,159,162,169],{"regimen":55,"formulation":23,"input":153,"expect":156},{"ageYears":154,"weightKg":155},60,70,{"perDose":157,"mlPerDose":158},31.5,0.32,{"regimen":82,"formulation":23,"input":160,"expect":161},{"ageYears":154,"weightKg":155},{"perDose":157,"mlPerDose":158},{"regimen":93,"formulation":23,"input":163,"expect":166},{"ageYears":164,"weightKg":165},6,20,{"perDose":167,"mlPerDose":168},9,0.09,{"regimen":105,"formulation":46,"input":170,"expect":172},{"ageYears":171,"weightKg":155},55,{"perDose":173,"mlPerDose":158},157.5,[175],"B03XA02",{"status":177,"forms":178,"refs":183},"registered",[179],{"code":180,"en":181,"fa":182},"18988","ARANESP 100MCG VIAL","ویال آرانسپ ۱۰۰ میکروگرم",[184],{"source":185,"section":186,"url":187},"darooyab-generic","G-1386\u002FDarbepoetin-Alfa","https:\u002F\u002Fwww.darooyab.ir\u002FG-1386\u002FDarbepoetin-Alfa",{"kind":189,"refs":190,"id":193},"BLA",[191],{"source":34,"section":192},"SPL approval \u002F marketing category","BLA103951",[195,198,202,206,209],{"kind":196,"url":197,"label":193},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=103951",{"kind":199,"url":200,"label":201},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9","FDA Aranesp",{"kind":203,"url":204,"label":205},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa604022.html","Darbepoetin Alfa Injection",{"kind":207,"url":208,"label":175},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B03XA02",{"kind":210,"url":187,"label":211},"darooyab","Darbepoetin-Alfa",{"pregnancy":213,"lactation":222,"pediatric":230,"geriatric":238},{"level":214,"text":215,"quote":218,"refs":219},"caution",{"fa":216,"en":217},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited available data on Aranesp use in pregnant women are insufficient to determine a drug-associated risk of major birth defects or miscarriage.",[220],{"source":34,"section":221},"8.1",{"level":214,"text":223,"quote":226,"refs":227},{"fa":224,"en":225},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of Aranesp in human milk, the effects on the breastfed child, or the effects on milk production.",[228],{"source":34,"section":229},"8.2",{"level":214,"text":231,"quote":234,"refs":235},{"fa":232,"en":233},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Pediatric Patients with CKD The safety and effectiveness of Aranesp in pediatric patients with CKD receiving and not receiving dialysis have been established in the age groups 1 month to 16 years old.",[236],{"source":34,"section":237},"8.4",{"level":214,"text":239,"quote":242,"refs":243},{"fa":240,"en":241},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the 1801 patients with CKD in clinical studies of Aranesp, 44% were age 65 and over, while 17% were age 75 and over.",[244],{"source":34,"section":245},"8.5",1792191536076]